Evidence map›Paper›PMID 26660518›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016

The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.

Vy Phan-Lai, Yushe Dang, Ekram Gad, Jennifer Childs, Mary L Disis

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. A Phase I/II Trial of HER2 Vaccine-Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2-Overexpressing Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  4. Article
  5. Article
  6. Review
  7. Follicular helper-T cells restore CD8Journal for immunotherapy of cancer · 2021
    Article
  8. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Article
  9. Review
  10. Article
  11. Toxoplasma: Immunity and Pathogenesis.Current clinical microbiology reports · 2019
    Article
  12. Frontiers in cellular and infection microbiology · 2019
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Vy Phan-LaiTumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle, Washington.
Yushe DangTumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle, Washington.
Ekram GadTumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle, Washington.
Jennifer ChildsTumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle, Washington.
Mary L DisisTumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle, Washington. ndisis@uw.edu.
Institute of Translational Health Sciences · USUniversity of Washington · US

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.R01CA136632 · NCI · UNIVERSITY OF WASHINGTON · PI COHEN, PETER A, DISIS, MARY L. · 2009 to 2014
$2.9M
Multi-Antigen Vaccines for Breast CancerR01CA101190 · NCI · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2003 to 2007
$1.7M
Nanotechnology and Physical Science Training Program in Cancer ResearchT32CA138312 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2009 to 2013
$1.5M
NCATS NIH HHS UL1 TR000423NCATS NIH HHS UL1 TR002319NCI NIH HHS R01 CA101190NCI NIH HHS R01 CA136632NCI NIH HHS T32 CA138312
6 · The paper itself

Abstract

purposeInfusion of HER2-specific T cells, derived from vaccine-primed patients and expanded with IL2/IL12, has induced tumor regression in a minority of patients with metastatic treatment-refractory HER2(+) breast cancer. We questioned whether alteration of cytokine growth factors used to culture vaccine-primed T cells could improve antitumor activity. EXPERIMENTAL

designUsing the TgMMTV-neu murine mammary tumor model, we cultured T cells derived from mice immunized with a previously defined neu class II peptide, p98-114 (neu p98), and evaluated different cytokine combinations for expansion.

resultsInfusion of neu p98-specific T-cell lines derived from all cytokine conditions evaluated resulted in significant antitumor activity compared with infused naïve splenocytes (P < 0.05). T cells cultured with IL2/IL21 could uniquely mediate complete regression of spontaneous mammary tumors. IL2/IL21 cultured neu-specific T cells demonstrated a different cytokine secretion pattern as compared with other cultured T cells; secreting high levels of TNFα and IL17 (P < 0.05). Moreover, tumor-infiltrating CD8(+) cells were significantly increased after the infusion of IL2/IL21 cultured T cells as compared with tumors treated with T cells expanded under other cytokine conditions (P < 0.001). The antitumor effect of the infusion of IL2/IL21 cultured cells was mediated by CD8 T cells. Depletion of TNFα or IL17, but not IFNγ, abrogated the tumor growth inhibition induced by the IL2/IL21 T cells and markedly decreased the influx of CD8 into tumors. Finally, IL2/IL21-cultured human antigen specific T cells also displayed a similar polyfunctional Th1/Th17 phenotype.

conclusionsExpansion of HER2 vaccine-primed T cells with IL2/IL21 may have the potential to effectively mediate tumor regression when used in adoptive transfer. Clin Cancer Res; 22(9); 2207-16. ©2015 AACR.

Indexed as

AnimalsBreast NeoplasmsCancer VaccinesCD8-Positive T-LymphocytesCell Line, TumorCytokinesErb-b2 Receptor Tyrosine KinasesFemaleHumansInterleukin-17Interleukin-2Interleukin-21InterleukinsLymphocytes, Tumor-InfiltratingMammary Neoplasms, ExperimentalMiceCancer VaccinesCytokinesErb-b2 Receptor Tyrosine KinasesInterleukin-17Interleukin-2Interleukin-21InterleukinsTumor Necrosis Factor-alpha

Identifiers

PMID26660518
PMCPMC4854769
OpenAlexW2282533970

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.